Venofer New Zealand - engelsk - Medsafe (Medicines Safety Authority)

venofer

pharmacy retailing (nz) ltd t/a healthcare logistics - iron sucrose 540 mg/ml equivalent to iron 20 mg/ml - solution for injection - 20 mg/ml - active: iron sucrose 540 mg/ml equivalent to iron 20 mg/ml excipient: water for injection - venofer is indicated for the treatment of iron deficiency in the following indications: · where there is a clinical need for a rapid iron supply, · in patients who cannot tolerate oral iron therapy or who are non-compliant, · in active inflammatory bowel disease where oral iron preparations are ineffective.

VENOFER iron 100mg/5mL (as iron(III) hydroxide sucrose complex) injection Australia - engelsk - Department of Health (Therapeutic Goods Administration)

venofer iron 100mg/5ml (as iron(iii) hydroxide sucrose complex) injection

seqirus pty ltd - iron sucrose, quantity: 540 mg/ml (equivalent: iron, qty 20 mg/ml) - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections - venofer is indicated for the treatment of iron deficiency anaemia in patients undergoing chronic haemodialysis and who are receiving supplemental erythropoietin therapy.,the diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. serum ferritin, serum iron, transferrin saturation and hypochromic red cells).

IRON DEXTRAN ( IRON SUCROSE INJECTION) Kenya - engelsk - Pharmacy and Poisons Board

iron dextran ( iron sucrose injection)

iron sucrose 100mg - injection - iron sucrose 100mg - antianemic preparations - iron preparations: iron

PMS-IRON SUCROSE SOLUTION Canada - engelsk - Health Canada

pms-iron sucrose solution

pharmascience inc - iron (iron sucrose) - solution - 20mg - iron (iron sucrose) 20mg - iron preparations

X- iron sucrose powder USA - engelsk - NLM (National Library of Medicine)

x- iron sucrose powder

ax pharmaceutical corp - iron sucrose (unii: fz7nyf5n8l) (iron sucrose - unii:fz7nyf5n8l) - iron sucrose 497.5 g in 500 g

FERROVIN Israel - engelsk - Ministry of Health

ferrovin

lapidot medical import and marketing ltd - iron sucrose - solution for injection - iron sucrose 20 mg/ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - ferrovin is indicated for the treatment of iron deficiency in the following indications:• where there is a clinical need for a rapid iron supply,• in patients who cannot tolerate oral iron therapy or who are non-compliant,• in active inflammatory bowel disease where oral iron preparations are ineffective,• in chronic kidney disease when oral iron preparations are less effective.the diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. hb (haemoglobin),serum ferritin, tsat (transferrin saturation), serum iron, etc.).

IRON SUCROSE Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

iron sucrose

ceva animal health pty ltd - iron-sucrose complex - unknown - iron-sucrose complex mineral- iorn base active 0.0 - active constituent

BUSPIRONE HYDROCHLORIDE tablet USA - engelsk - NLM (National Library of Medicine)

buspirone hydrochloride tablet

redpharm drug, inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 5 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual du

BUSPIRONE HYDROCHLORIDE tablet USA - engelsk - NLM (National Library of Medicine)

buspirone hydrochloride tablet

preferred pharmaceuticals inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 15 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual d

BUSPIRONE HYDROCHLORIDE tablet USA - engelsk - NLM (National Library of Medicine)

buspirone hydrochloride tablet

preferredpharmaceuticals inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 10 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual d